製品番号: HY-15005

Copy Link Print Information

Sofosbuvir

(別名: GS-7977; PSI-7977)

118 Cited Publications

カスタマーレビュー

Based on 118 publication(s) in Google Scholar

Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC₅₀ of 92 nM.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.97%
CAS 番号: 1190307-88-0
分子式: C₂₂H₂₉FN₃O₉P
分子量:529.45

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Sofosbuvir 構造式

CAS 番号: 1190307-88-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 臨床実験
化学情報
Publications (118)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC₅₀ of 92 nM^[1].

IC₅₀ & Target

EC50: 92±5 nM (HCV)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
Calu-3	CC₅₀	512 μM Compound: Sofosbuvir	Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay	[PMID: 36965227]
Cardiac muscle cell	CC₅₀	>300 μM Compound: SOF	Cardiotoxicity against human embryonic stem cell-induced ventricular cardiomyocytes administered on day 7 and measured on day 10 after 30 mins incubation by CellTiter Glo assay Cardiotoxicity against human embryonic stem cell-induced ventricular cardiomyocytes administered on day 7 and measured on day 10 after 30 mins incubation by CellTiter Glo assay	[PMID: 30653317]
CCRF-CEM	CC₅₀	>100 μM Compound: 1; SOF	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay	[PMID: 28595015]
CCRF-CEM	CC₅₀	>100 μM Compound: Sofosbuvir	Cytotoxicity against human CEM cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay Cytotoxicity against human CEM cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	[PMID: 29066308]
CCRF-CEM	CC₅₀	>100 μM Compound: SOF	Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay	[PMID: 30653317]
CCRF-CEM	CC₅₀	>100 μM Compound: SOF; 1	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method	[PMID: 30655167]
HepaRG	CC₅₀	44 μM Compound: SOF	Cytotoxicity in human HepaRG cells assessed as reduction in cell viability incubated for 14 days by CellTiter-Glo assay Cytotoxicity in human HepaRG cells assessed as reduction in cell viability incubated for 14 days by CellTiter-Glo assay	[PMID: 30653317]
Hepatocyte	CC₅₀	>300 μM Compound: SOF	Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30653317]
HepG2	IC₅₀	>50 μM Compound: 1; SOF	Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method	[PMID: 28595015]
HepG2	IC₅₀	>50 μM Compound: 1; SOF	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method	[PMID: 28595015]
HepG2	CC₅₀	>50 μM Compound: Sofosbuvir	Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay	[PMID: 29801997]
HepG2	IC₅₀	>50 μM Compound: SOF	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	[PMID: 30653317]
HepG2	IC₅₀	45 μM Compound: SOF	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	[PMID: 30653317]
HK-2	CC₅₀	>300 μM Compound: SOF	Nephrotoxicity in human HK2 cells after 72 hrs by Hoechst 33342/HCS live/dead green dye-based assay Nephrotoxicity in human HK2 cells after 72 hrs by Hoechst 33342/HCS live/dead green dye-based assay	[PMID: 30653317]
Huh-7	EC₅₀	0.254 μM Compound: 25	Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay	[PMID: 24345201]
Huh-7	CC₅₀	>100 μM Compound: PSI-7977	Cytotoxicity against human Huh7.5.1 cells after 48 hrs by luciferase reporter gene assay Cytotoxicity against human Huh7.5.1 cells after 48 hrs by luciferase reporter gene assay	[PMID: 27994763]
Huh-7	EC₅₀	0.12 μM Compound: PSI-7977	Antiviral activity against HCV JFH-1 infected in human HuH7.5.1 cells after 48 hrs by luciferase reporter gene assay Antiviral activity against HCV JFH-1 infected in human HuH7.5.1 cells after 48 hrs by luciferase reporter gene assay	[PMID: 27994763]
Huh-7	CC₅₀	>10 μM Compound: 1; SOF	Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay	[PMID: 28595015]
Huh-7	CC₅₀	>10 μM Compound: Sofosbuvir	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by MTT assay	[PMID: 29066308]
Huh-7	CC₅₀	>1000 μM Compound: 17	Cytotoxicity against human HuH7 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human HuH7 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 29172078]
Huh-7	CC₅₀	>100 μM Compound: SOF	Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay	[PMID: 30653317]
Huh-7	CC₅₀	>100 μM Compound: SOF; 1	Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels after 5 days by RT-PCR analysis Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels after 5 days by RT-PCR analysis	[PMID: 30655167]
Huh-7	CC₅₀	>20 μM Compound: Sofosbuvir	Cytotoxicity against human HuH7 cells infected with HCV genotype 1b replicon after 72 hrs by CellTiter-Fluor reagent based fluorescence assay Cytotoxicity against human HuH7 cells infected with HCV genotype 1b replicon after 72 hrs by CellTiter-Fluor reagent based fluorescence assay	[PMID: 30683552]
Huh-7	EC₅₀	0.053 μM Compound: 1	Antiviral activity against HCV genotype 1b Con1 over expressing CES1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1b Con1 over expressing CES1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 31740203]
Huh-7	EC₅₀	0.062 μM Compound: 1	Antiviral activity against HCV genotype 1b Con1 expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 1b Con1 expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.0751 μM Compound: 1	Antiviral activity against HCV genotype 3a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 3a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.0785 μM Compound: 1	Antiviral activity against HCV genotype 4a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 4a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.0867 μM Compound: 1	Antiviral activity against HCV genotype 6a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 6a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.155 μM Compound: 1	Antiviral activity against HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 31740203]
Huh-7	EC₅₀	0.188 μM Compound: 1	Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 31740203]
Huh-7	EC₅₀	0.3301 μM Compound: 1	Antiviral activity against HCV genotype 3a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 3a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.6376 μM Compound: 1	Antiviral activity against HCV genotype 1b Con1 expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 1b Con1 expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.6813 μM Compound: 1	Antiviral activity against HCV genotype 2a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 2a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	1.002 μM Compound: 1	Antiviral activity against HCV genotype 2a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay Antiviral activity against HCV genotype 2a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay	[PMID: 31740203]
Huh-7	EC₅₀	0.155 μM Compound: Sofosbuvir	Inhibition of NS5B polymerase in HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Inhibition of NS5B polymerase in HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 32046903]
Huh-7	EC₅₀	0.23 μM Compound: Sofosbuvir	Inhibition of NS5B polymerase in HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay Inhibition of NS5B polymerase in HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay	[PMID: 32046903]
Huh-7	CC₅₀	200 μM Compound: Sofosbuvir	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 32435411]
Huh-7	IC₅₀	3.8 μM Compound: Sofosbuvir	Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infecte Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infecte	[PMID: 32435411]
Huh-7	CC₅₀	200 μM Compound: Sofosbuvir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay	[PMID: 34273661]
Huh-7	CC₅₀	>100 μM Compound: SOF	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by viral-Tox-glo assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by viral-Tox-glo assay	[PMID: 37159959]
Huh-7.5	CC₅₀	>200 μM Compound: SOF	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35050619]
Huh-7.5	CC₅₀	121.47 μM Compound: SOF	Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35050619]
Huh-7.5	CC₅₀	170.85 μM Compound: SOF	Cytotoxicity against human Huh7.5 cells infected with HCVcc assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells infected with HCVcc assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35050619]
Huh-7.5	CC₅₀	>200 μM Compound: Sofosbuvir	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by CCK-8 assay Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by CCK-8 assay	[PMID: 38561238]
PBMC	CC₅₀	>100 μM Compound: 1; SOF	Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay	[PMID: 28595015]
PBMC	CC₅₀	>100 μM Compound: Sofosbuvir	Cytotoxicity against human PBMC assessed as reduction in cell viability after 6 days by trypan blue exclusion assay Cytotoxicity against human PBMC assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	[PMID: 29066308]
PBMC	CC₅₀	>100 μM Compound: SOF	Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay	[PMID: 30653317]
PBMC	CC₅₀	>100 μM Compound: SOF; 1	Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method	[PMID: 30655167]
Vero	CC₅₀	>100 μM Compound: 1; SOF	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay	[PMID: 28595015]
Vero	CC₅₀	>100 μM Compound: Sofosbuvir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay	[PMID: 29066308]
Vero	CC₅₀	>100 μM Compound: SOF	Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay	[PMID: 30653317]
Vero	CC₅₀	>100 μM Compound: SOF; 1	Cytotoxicity against African green monkey Vero cells after 3 days by hemocytometric method Cytotoxicity against African green monkey Vero cells after 3 days by hemocytometric method	[PMID: 30655167]
Vero	CC₅₀	360 μM Compound: 5	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 31549836]
Vero	EC₅₀	30.9 μM Compound: 5	Inhibition of RNA-dependent RNA polymerase in Zika virus infected in African green monkey Vero cells assessed as antiviral activity by DAPI-staining based assay Inhibition of RNA-dependent RNA polymerase in Zika virus infected in African green monkey Vero cells assessed as antiviral activity by DAPI-staining based assay	[PMID: 31549836]

体外実験

When cathepsin A (CatA) is incubated with PSI-7977 or Sofosbuvir (PSI-7977) for 150 min, ~18-fold more PSI-352707 is formed when Sofosbuvir (PSI-7977) is the substrate compared with PSI-7976. Moreover, the catalytic efficiency for Sofosbuvir (PSI-7977) with CatA is ~30-fold higher than that for PSI-7976^[1]. The genotype coverage of Sofosbuvir (PSI-7977) by using GT 1b (Con1)-, 1a (H77)-, and 2a (JFH-1)-derived replicons and GT 1b chimeric replicons containing the NS5B region from the J6 GT 2a isolate and from GT 2b and GT 3a patient isolates is evaluated, Sofosbuvir (PSI-7977) inhibits the replication of these replicons with similar EC₅₀s (between 16 and 48 nM), and is especially active against the chimeric replicon containing the J6 NS5B (EC₅₀=4.7 nM). Sofosbuvir (PSI-7977) inhibits clone A (GT 1b) wild-type and S282T replicons with EC₉₀ values of 0.42 and 7.8 μM, respectively^[2]. In the clone A replicon assay, Sofosbuvir (PSI-7977) produces anti-HCV activity with EC₉₀ values 0.42 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 1190307-88-0
性状 Solid
分子量 529.45
分子式 C₂₂H₂₉FN₃O₉P
Color White to off-white
SMILES

C[C@@]1(F)[C@H](O)[C@@H](CO[P@](OC2=CC=CC=C2)(N[C@@H](C)C(OC(C)C)=O)=O)O[C@H]1N(C=CC(N3)=O)C3=O
別名

GS-7977; PSI-7977
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (118)

All Microbiological AssayBio/Physico-chemical AssayRT-PCRWB

Sort by:

Journal Impact Factor

Nat Med

Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. [Abstract]

2014 Aug;20(8):927-35. PMID: 25064127
Cell

Structural basis for human Cav1.2 inhibition by multiple drugs and the neurotoxin calciseptine. [Abstract]

2023 Nov 22;186(24):5363-5374.e16. PMID: 37972591
Cell

Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Cav channels. [Abstract]

2022 Dec 8;185(25):4801-4810.e13. PMID: 36417914
Nat Immunol

NLRX1 promotes immediate IRF1-directed antiviral responses by limiting dsRNA-activated translational inhibition mediated by PKR. [Abstract]

2017 Dec;18(12):1299-1309. PMID: 28967880
Gastroenterology

Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. [Abstract]

2015 Feb;148(2):392-402.e13. PMID: 25447848
Nat Microbiol

Basal expression of interferon regulatory factor 1 drives intrinsic hepatocyte resistance to multiple RNA viruses. [Abstract]

2019 Jul;4(7):1096-1104. PMID: 30988429
Nucleic Acids Res

CSNK2B modulates IRF1 binding to functional DNA elements and promotes basal and agonist-induced antiviral signaling. [Abstract]

2023 May 22;51(9):4451-4466. PMID: 37094077
Nucleic Acids Res

TNRC6 proteins modulate hepatitis C virus replication by spatially regulating the binding of miR-122/Ago2 complexes to viral RNA. [Abstract]

2019 Jul 9;47(12):6411-6424. PMID: 30997501

Sofosbuvir purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2019 Jul 9;47(12):6411-6424. [Abstract]

Positive-strand HCV RNA stability in cells following Sofosbuvir (10 μM) arrest of viral RNA synthesis. HCV RNA level at 0 h was arbitrarily set to 100%.
Nucleic Acids Res

Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3΄ variants. [Abstract]

2017 May 5;45(8):4743-4755. PMID: 28082397

Sofosbuvir purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2017 May 5;45(8):4743-4755. [Abstract]

PH5CH8 cells were co-electroporated with HCV JFH1/GLuc RNA and the (left) 23-3΄U variant or (right) 23-3΄Up6 mutant, then cultured in the presence or absence of the NS5B inhibitor sofosbuvir (SOF). As negative controls for viral RNA amplification, parallel cultures were co-electroporated with miR-124 or a non-replicating HCV RNA containing a lethal GND mutation in the NS5B polymerase. Secreted GLuc activity was followed at intervals.
Cell Rep Med

Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery. [Abstract]

2026 Mar 9:102646. PMID: 41806841
Genomics Proteomics Bioinformatics

NSUN2-mediated HCV RNA m5C Methylation Facilitates Viral RNA Stability and Replication. [Abstract]

2025 May 10;23(1):qzaf008. PMID: 39957240

Sofosbuvir purchased from MedChemExpress. Usage Cited in: Genomics Proteomics Bioinformatics. 2025 May 10;23(1):qzaf008. [Abstract]

WB assays of the expression of NSUN2 as well as HCV NS3 and Core proteins in Huh7.5.1 cells treated with Sofosbuvir (0-10 μM) or in combination with SAH at the indicated concentrations at 6 h post infection, and then harvested at 72 h post infection.

Sofosbuvir purchased from MedChemExpress. Usage Cited in: Genomics Proteomics Bioinformatics. 2025 May 10;23(1):qzaf008. [Abstract]

WB assays of the expression of NSUN2 as well as HCV NS3 and Core proteins in Huh7.5.1 cells treated with Sofosbuvir (0-10 μM) or in combination with sinefungin at the indicated concentrations at 6 h post infection, and then harvested at 72 h post infection.
Br J Pharmacol

Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-κB- and MAPK-ERK1/2-mediated COX-2 expression. [Abstract]

2015 Sep;172(18):4481-4492. PMID: 26102077

Sofosbuvir purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2015 Sep;172(18):4481-4492. [Abstract]

Ava5 cells were treated with a combination of BA and IFN-α, telaprevir or sofosbuvir at various concentrations for 3 days. Total RNA was extracted and the levels of HCV RNA were quantified by qRT-PCR analysis.
Br J Pharmacol

Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells. [Abstract]

2014 Jan;171(1):237-52. PMID: 24117426
JHEP Rep

Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment. [Abstract]

2024 Jan 3;6(3):100989. PMID: 38434938
Biomed Pharmacother

A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. [Abstract]

2019 Aug:116:108976. PMID: 31103827
J Med Chem

2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. [Abstract]

2020 Jun 11;63(11):5972-5989. PMID: 32378892
J Med Chem

Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1. [Abstract]

2016 Nov 23;59(22):10268-10284. PMID: 27783522

Sofosbuvir purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Nov 23;59(22):10268-10284. [Abstract]

Huh7.5 cells are infected with HCV (45 IU/cell) and simultaneously treated with Simeprevir (A, 0.025 μM), Sofosbuvir (B, 0.1 μM), or Daclatasvir (C, 16 pM) alone or with 1 (6.25 μM).
Int J Radiat Oncol Biol Phys

Targeting Phosphatidylinositol 4-Kinase IIIα for Radiosensitization: A Potential Model of Drug Repositioning Using an Anti-Hepatitis C Viral Agent. [Abstract]

2016 Nov 15;96(4):867-876. PMID: 27788957
EMBO Rep

Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication. [Abstract]

2016 Jul;17(7):1013-28. PMID: 27283940
Eur J Med Chem

System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. [Abstract]

2021 Nov 15:224:113683. PMID: 34273661
Eur J Med Chem

Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. [Abstract]

2018 Jan 1:143:1053-1065. PMID: 29232582

Sofosbuvir purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2018 Jan 1:143:1053-1065. [Abstract]

GS4.3 cells are treated with 7f (20 μM), or Telaprevir (0.5μM), Sofosbuvir (0.8 μM), Daclatasvir (0.15 μM) or solvent control for 6 days.

Sofosbuvir purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2018 Jan 1:143:1053-1065. [Abstract]

Huh7.5 cells are infected with HCV and simultaneously treated with 7f (10 μM) or DAA (0.04 μM Simeprevir, 0.08 μM Sofosbuvir, or 16 pM Daclatasvir) or 7f plus DAA.
Pharmaceutics

Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection. [Abstract]

2021 Oct 11;13(10):1656. PMID: 34683949
J Gastroenterol

Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. [Abstract]

2019 May;54(5):449-458. PMID: 30684016
Cells

Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems. [Abstract]

2022 Mar 8;11(6):927. PMID: 35326378
Cells

Differential Roles of Lipin1 and Lipin2 in the Hepatitis C Virus Replication Cycle. [Abstract]

2019 Nov 18;8(11):1456. PMID: 31752156
Microchem J

2025 Nov 1;219:116018.
Int J Mol Sci

Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro. [Abstract]

2021 Mar 6;22(5):2670. PMID: 33800884
PLoS Pathog

NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains. [Abstract]

2017 Jun 8;13(6):e1006343. PMID: 28594932
PLoS Pathog

Characterization of miR-122-independent propagation of HCV. [Abstract]

2017 May 11;13(5):e1006374. PMID: 28494029
PLoS Pathog

Spatiotemporal analysis of hepatitis C virus infection. [Abstract]

2015 Mar 30;11(3):e1004758. PMID: 25822891
Pharmaceuticals (Basel)

Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. [Abstract]

2022 Feb 18;15(2):242. PMID: 35215354
Front Pharmacol

Bicyclol Attenuates Liver Inflammation Induced by Infection of Hepatitis C Virus via Repressing ROS-Mediated Activation of MAPK/NF-κB Signaling Pathway. [Abstract]

2018 Dec 19:9:1438. PMID: 30618739
Front Pharmacol

Grape Seed Extract Attenuates Hepatitis C Virus Replication and Virus-Induced Inflammation. [Abstract]

2016 Dec 21:7:490. PMID: 28066241
Bioorg Chem

Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses. [Abstract]

2023 Apr:133:106408. PMID: 36801791
Eur J Pharmacol

Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process. [Abstract]

2020 Sep 15;883:173323. PMID: 32622669
J Med Virol

Monkeypox Virus Is Inhibited by Nucleoside Analogues Including the Acyclic Phosphonates Adefovir and Tenofovir In Vitro. [Abstract]

2025 Nov;97(11):e70669. PMID: 41137742
J Med Virol

A Pyrido-Quinoxaline Derivative That Downregulates Reticulon 3 Protein Exhibits Potent Antiviral Activity Against Zika Virus. [Abstract]

2025 Sep;97(9):e70605. PMID: 40966184
Molecules

Roseoside Is a Bioactive Compound in Kirengeshoma koreana Nakai Extract with Potent In Vitro Antiviral Activity Against Hepatitis C Virus. [Abstract]

2024 Oct 30;29(21):5130. PMID: 39519772
J Med Virol

Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon. [Abstract]

2023 Dec;95(12):e29290. PMID: 38102947
Hepatol Commun

Genotype 5 Hepatitis E Virus Produced by a Reverse Genetics System Has the Potential for Zoonotic Infection. [Abstract]

2018 Nov 30;3(1):160-172. PMID: 30620002
Hepatol Commun

Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor α. [Abstract]

2017 Jul 13;1(6):550-563. PMID: 29404478
Nanomedicine

Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture. [Abstract]

2017 Jan;13(1):49-58. PMID: 27562210
Int J Antimicrob Agents

Differential inhibition features of direct-acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1. [Abstract]

2015 Oct;46(4):381-8. PMID: 26163159
Antimicrob Agents Chemother

Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase. [Abstract]

2020 Dec 16;65(1):e01508-20. PMID: 33122171
Antimicrob Agents Chemother

Antiviral Candidates for Treating Hepatitis E Virus Infection. [Abstract]

2019 May 24;63(6). pii: e00003-19. PMID: 30885901
Front Microbiol

Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry. [Abstract]

2017 Jun 19:8:1129. PMID: 28674529
Antimicrob Agents Chemother

Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. [Abstract]

2015 May;59(5):2496-507. PMID: 25666154
Antimicrob Agents Chemother

Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. [Abstract]

2014 Aug;58(8):4555-64. PMID: 24867984
Antimicrob Agents Chemother

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. [Abstract]

2014 Jun;58(6):3327-34. PMID: 24687498
Antimicrob Agents Chemother

Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction. [Abstract]

2013 Mar;57(3):1180-91. PMID: 23254429
Ann Hepatol

Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure. [Abstract]

Nov-Dec 2019;18(6):816-824. PMID: 31594756
J Gen Virol

Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. [Abstract]

2021 Dec;102(12). PMID: 34949310
J Cell Mol Med

TGF-β isoforms inhibit hepatitis C virus propagation in transforming growth factor beta/SMAD protein signalling pathway dependent and independent manners. [Abstract]

2021 Apr;25(7):3498-3510. PMID: 33682288
Antiviral Res

Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro. [Abstract]

2026 Feb 27:106381. PMID: 41765050
Antiviral Res

Effectiveness of nucleoside analogs against Wetland virus infection. [Abstract]

2025 Apr:236:106114. PMID: 39954869
Virol Sin

Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]

2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635
Antiviral Res

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. [Abstract]

2022 Jan:197:105224. PMID: 34864126
Antiviral Res

Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. [Abstract]

2020 May;177:104734. PMID: 32057770
Antiviral Res

Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. [Abstract]

2020 Mar;175:104708. PMID: 31931104
Antiviral Res

Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. [Abstract]

2019 Nov;171:104612. PMID: 31542377
Antiviral Res

Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro. [Abstract]

2019 Oct;170:104570. PMID: 31362004
Antiviral Res

Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. [Abstract]

2017 Dec:148:5-14. PMID: 29074218
Antiviral Res

Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells. [Abstract]

2017 Oct:146:191-200. PMID: 28935193
Antiviral Res

A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. [Abstract]

2017 Mar;139:18-24. PMID: 28025084
Antiviral Res

Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. [Abstract]

2016 Aug:132:287-95. PMID: 27387825
Antiviral Res

Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals. [Abstract]

2013 Jul;99(1):6-11. PMID: 23660623
Sci Rep

Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration. [Abstract]

2025 Aug 2;15(1):28197. PMID: 40750837
Sci Rep

5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry. [Abstract]

2019 May 13;9(1):7288. PMID: 31086268
Sci Rep

Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. [Abstract]

2019 Apr 5;9(1):5722. PMID: 30952914
Sci Rep

Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression. [Abstract]

2018 Jun 6;8(1):8676. PMID: 29875371
Sci Rep

Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. [Abstract]

2016 Oct 5;6:34652. PMID: 27703205
Mol Divers

Repurposed drugs as PCSK9-LDLR disruptors for lipid lowering and cardiovascular disease therapeutics. [Abstract]

2024 Dec 8. PMID: 39645639
J Virol

Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection. [Abstract]

2021 Apr 26;95(10):e02057-20. PMID: 33627392
J Virol

Novel permissive cell lines for complete propagation of hepatitis C virus. [Abstract]

2014 May;88(10):5578-94. PMID: 24599999
Viruses

Identification and Tracking of Antiviral Drug Combinations. [Abstract]

2020 Oct 18;12(10):1178. PMID: 33080984
Viruses

Generation of Combinatorial Lentiviral Vectors Expressing Multiple Anti-Hepatitis C Virus shRNAs and Their Validation on a Novel HCV Replicon Double Reporter Cell Line. [Abstract]

2020 Sep 18;12(9):1044 PMID: 32962117
Viruses

Potential Therapeutic Agents for Feline Calicivirus Infection. [Abstract]

2018 Aug 16;10(8). pii: E433. PMID: 30115859
Hepatol Res

Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin. [Abstract]

2018 Feb;48(3):E347-E353. PMID: 28834004
Chem Biol Drug Des

Sofosbuvir as treatment against dengue?. [Abstract]

2018 Feb;91(2):448-455. PMID: 28834304
Bioorg Med Chem

Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus. [Abstract]

2019 Feb 1;27(3):560-567. PMID: 30606673
J Chromatogr B Analyt Technol Biomed Life Sci

Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS. [Abstract]

2019 Mar 15:1110-1111:15-24. PMID: 30776611
SLAS Discov

Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. [Abstract]

2020 Jun;25(5):506-514. PMID: 32186426
Virus Res

Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro. [Abstract]

2018 Jan 15:244:64-70. PMID: 29113824
Virus Res

Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems. [Abstract]

2017 May 2:235:37-48. PMID: 28322919
PLoS One

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. [Abstract]

2021 May 20;16(5):e0251934. PMID: 34014993
PLoS One

Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice. [Abstract]

2020 Aug 7;15(8):e0237236. PMID: 32764799
Transpl Infect Dis

The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype. [Abstract]

2018 Feb;20(1). PMID: 29111569
PLoS One

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection. [Abstract]

2016 Jul 21;11(7):e0159511. PMID: 27442520
PLoS One

Distinct Roles for Intracellular and Extracellular Lipids in Hepatitis C Virus Infection. [Abstract]

2016 Jun 9;11(6):e0156996. PMID: 27280294
PLoS One

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175. [Abstract]

2016 Apr 22;11(4):e0152036. PMID: 27104614
PLoS One

Sulforaphane Suppresses Hepatitis C Virus Replication by Up-Regulating Heme Oxygenase-1 Expression through PI3K/Nrf2 Pathway. [Abstract]

2016 Mar 29;11(3):e0152236. PMID: 27023634
Biomed Res Int

A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System. [Abstract]

2017:2017:1236801. PMID: 28904942

Sofosbuvir purchased from MedChemExpress. Usage Cited in: Biomed Res Int. 2017:2017:1236801. [Abstract]

Huh7.5 (HCV+) cells are treated with 1 μM of Sofosbuvir or solvent control. At 24 hours, the cells are washed and continuously incubated with fresh culture media containing drugs again for 48 hours. The cultural supernatants are then harvested and directly incubated to naïve Huh7.5 cells. After been passaged 1~3 times, the newly infected cells are treated with 1 μM of Sofosbuvir for 72 hours. Intracellular proteins are extracted and detected with WB.
Biochem Biophys Res Commun

Sofosbuvir and its tri-phosphate metabolite inhibit the RNA-dependent RNA polymerase activity of non-structural protein 5 from the Kyasanur forest disease virus. [Abstract]

2023 Jan 22:641:50-56. PMID: 36521285
Curr Drug Metab

Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan. [Abstract]

2022;23(12):1000-1010. PMID: 36515038
Biomed Chromatogr

In-depth investigation of the Silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 and ledipasvir in rat plasma using LC-MS. [Abstract]

2022 Sep;36(9):e5427. PMID: 35708053
J Virol Methods

Screening of novel drugs for inhibiting hepatitis E virus replication. [Abstract]

2019 Aug:270:1-11. PMID: 31004661
Nat Prod Res

Two new sesquiterpene glycosides isolated from the fresh needles of Pinus massoniana Lamb. [Abstract]

2017 Feb;31(3):341-346. PMID: 27825248
J Virol Methods

A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening. [Abstract]

2015 Jun 15;218:59-65. PMID: 25796989
bioRxiv

2026 Feb 4.
bioRxiv

Drug-induced phospholipidosis as an artifact in antiviral drug repurposing. [Abstract]

2025 Nov 21:2025.11.20.689520. PMID: 41332603
bioRxiv

2025 August 15.
University of Veterinary Medicine Hannover

2025.
bioRxiv

Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo. [Abstract]

2025 Jan 25:2025.01.24.633564. PMID: 39896535
University of Colorado Denver

2024.
Preprints

2024 Feb 19.
SSRN

2024 Jan 23.
bioRxiv

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity. [Abstract]

2023 Aug 20:2023.08.19.553982. PMID: 37645728
SSRN

2023 Mar 30.
Norwegian University of Science and Technology

2021 Oct.
bioRxiv

2020 May.
bioRxiv

2020 Apr.
University Estadual De Campinas Institudo De Biologia

2019 Sep.
bioRxiv

2019 Aug.
Charles University

2019 Jun.
Charles University

2019 Jun.
Seoul National University

2016 Aug.
Universidad Autónoma de Madrid

2016 Jan 12.
Open Virol J

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells. [Abstract]

2014 Mar 7;8:1-8. PMID: 24799968

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (94.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 25 mg/mL (47.22 mM; ultrasonic and warming and heat to 50°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8888 mL

9.4438 mL

18.8875 mL

5 mM

0.3778 mL

1.8888 mL

3.7775 mL

10 mM

0.1889 mL

0.9444 mL

1.8888 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (3.15 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.67 mg/mL (3.15 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (3.15 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 4.55 mg/mL (8.59 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

プロトコル

Cell Assay^[1]

Clone A cells are seeded into T75 flasks at about 5×10⁶ cells/flask in Dulbecco's modified Eagle's medium (DMEM) containing 100 IU/mL Penicillin/100 μg/mL streptomycin and 10% fetal bovine serum. Similarly, human primary hepatocytes are seeded in cell plating medium into T75 flasks at about 5×10⁶ cells/flask. After overnight incubation to allow the cells to attach, cells are incubated with 50 μM PSI-7851, PSI-7976, or Sofosbuvir (PSI-7977) in fresh medium for clone A cells or in cell maintenance medium for primary hepatocytes for up to 24 h at 37°C in a 5% CO₂ atmosphere. The same procedures are applied when radiolabeled PSI-7851 is used in the study except that 1×10⁶ cells per well are seeded into a 6-well plate, and the cells are incubated with 5 μM [³H]PSI-7851. At selected times, the medium is removed, and the cell layer is washed with cold phosphate-buffered saline (PBS). After trypsinization, cells are counted and centrifuged at 1,200 rpm for 5 min. The cell pellets are suspended in 1 mL of cold 60% methanol and incubated overnight at −20°C. The samples are centrifuged at 14,000 rpm for 5 min, and the supernatants are collected and dried using a SpeedVac concentrator and stored at −20°C until they are analyzed by high performance liquid chromatography (HPLC). Residues are suspended in 100 μL of water, and 50-μL aliquots are injected into HPLC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem. 2010 Nov 5;285(45):34337-47. [Content Brief]

[2]. Lam AM, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68. [Content Brief]

[3]. Sofia MJ, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010 Oct 14;53(19):7202-18. [Content Brief]

[4]. Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.8888 mL	9.4438 mL	18.8875 mL	47.2188 mL
	5 mM	0.3778 mL	1.8888 mL	3.7775 mL	9.4438 mL
	10 mM	0.1889 mL	0.9444 mL	1.8888 mL	4.7219 mL
	15 mM	0.1259 mL	0.6296 mL	1.2592 mL	3.1479 mL
	20 mM	0.0944 mL	0.4722 mL	0.9444 mL	2.3609 mL
	25 mM	0.0756 mL	0.3778 mL	0.7555 mL	1.8888 mL
	30 mM	0.0630 mL	0.3148 mL	0.6296 mL	1.5740 mL
	40 mM	0.0472 mL	0.2361 mL	0.4722 mL	1.1805 mL
DMSO	50 mM	0.0378 mL	0.1889 mL	0.3778 mL	0.9444 mL
	60 mM	0.0315 mL	0.1574 mL	0.3148 mL	0.7870 mL
	80 mM	0.0236 mL	0.1180 mL	0.2361 mL	0.5902 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Sofosbuvir

118 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Sofosbuvir

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Classic FDA-Approved Drug Library

MedChemExpress（MCE）の使用を引用している文献 Sofosbuvir

生物活性

化学情報

Publications (118)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Sofosbuvir

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Classic FDA-Approved Drug Library

MedChemExpress（MCE）の使用を引用している文献 Sofosbuvir

生物活性

化学情報

Publications (118)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Sofosbuvir 関連分類

製品番号: HY-15005